Results 151 to 160 of about 25,216 (236)

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, Volume 13, Issue 14, 9 March 2026.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Linvoseltamab in multiple myeloma: a BCMA × CD3 bispecific antibody for relapsed and refractory disease. [PDF]

Ann Med Surg (Lond)
Khan G, Haider E, Imtiaz A, Ekouo J.
europepmc   +1 more source

Cutaneous Toxicities Associated With Amivantamab in Patients With Non‐Small Cell Lung Cancer: A Systematic Review

International Journal of Dermatology, EarlyView.
Ioannis‐Alexios Koumprentziotis, Aikaterini Bakella, Antonis Tsimpidakis, Alexander Stratigos, Vasiliki Nikolaou   +4 more
wiley   +1 more source

Extramedullary Disease—Achilles Heel in Myeloma?

American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar, Joshua Richter, Saad Z. Usmani, Yael C. Cohen, Jing Christine Ye, María‐Victoria Mateos, Vania Hungria, Elena Zamagni   +7 more
wiley   +1 more source

A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F. [PDF]

J Biol Chem
Tian H, Fung CP, Burman L, Chong YE, Liu C, Geng Y, Yang L, Chow MW, Zhang Y, Ho KWH, Zhu G, Wu Z, Yang XL, Xu Z, Nangle LA.   +14 more
europepmc   +1 more source

Development of a High‐Throughput LC–MS/MS Method for Simultaneous Quantification of Four Therapeutic Monoclonal Antibodies in Human Serum: Application in Clinical Therapeutic Drug Monitoring

Biomedical Chromatography, Volume 40, Issue 3, March 2026.
ABSTRACT Monoclonal antibody (mAb) therapies have revolutionized cancer treatment, significantly improving patient outcomes. However, the pharmacokinetics (PK) and pharmacodynamics (PD) of mAbs exhibit considerable variability due to nonlinear kinetics and individual differences, highlighting the need for therapeutic drug monitoring (TDM).
Yuan Yao, Guang‐Yao Huang, Ting‐Ting Wu, Ting‐Fei Tan, Feng‐Mei Hu, Chao Huang, Shan Gao, An‐Ping Guo, Jun‐Ping Wang   +8 more
wiley   +1 more source

Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance. [PDF]

J Immunother Cancer
Nan L, Chen L, Huang W, Peng S, Wang C, Liao H, Wang Y, Cui Z, Lv Y, Wang X, Luo Y, Tsun A, Miao X, Zhang J.   +13 more
europepmc   +1 more source

Bispecific Antibody 4G7xH22 [PDF]

, 2020
openaire   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Evaluation of Anticancer Therapy‐Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Aim Tumor flare reaction (TFR) is characterized by an increase in tumor size during immunotherapy, often resembling disease progression. This study explores the relationship between anti‐tumor drugs and tumor flare reaction (TFR) through the FAERS database to assist clinicians in better patient management.
Wei Wang, Jiayuan Cui, Yuxuan Bo, Yuxuan Wang, Zhipeng Sun, Xin Guan, Baoan Hong, Ning Zhang   +7 more
wiley   +1 more source